marketing

Teva’s DuoResp Spiromax receives EC marketing authorization for treatment of … – News-Medical.net

Teva's DuoResp Spiromax receives EC marketing authorization for treatment of …News-Medical.netTeva Pharmaceutical Industries Ltd., (NYSE:TEVA) announced today that the European Commission has granted marketing authorization for DuoResp Spiromax® for the treatment of patients with asthma and chronic obstructive pulmonary disease…